Vanda Pharmaceuticals | VNDA - DEBITO





DEBITO Cambiamento Data
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Akebia Therapeutics USD 46.51M 7.82M 2025-03
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 312.77M 53.52M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Eli Lilly USD 42.5B 3.6M 2025-12
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Esperion Therapeutics USD 262.92M 1.76M 2024-09
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Heron Therapeutics USD 149.65M 157K 2024-09
Insmed USD 727.62M 275K 2026-03
J&J USD 47.93B 2.14B 2025-12
Lexicon Pharmaceuticals USD 99.51M 243K 2023-12
Ligand Pharmaceuticals USD 451.49M 494K 2025-12
Merck USD 49.34B 7.97B 2025-12
Minerva Neurosciences USD 0 0 2024-09
Moderna USD 1.31B 571M 2025-12
Novartis USD 47B 14.98B 2026-03
Pfizer USD 63.73B 231M 2026-03
PTC Therapeutics USD 286.94M 2.42B 2026-03
Puma Biotechnology USD 89.06M 55.07M 2024-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 20.33B 1.43B 2025-12
Takeda JPY 4.85T 208B 2025-12
Teva Pharmaceutical Industries USD 17.09B 21M 2025-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12
Veracyte USD 39.65M 799K 2025-12